home / stock / ocup / ocup news

OCUP News and Press, Ocuphire Pharma Inc Com From 06/21/23

Stock Information
Company Name: Ocuphire Pharma Inc Com
Stock Symbol: OCUP
Market: NASDAQ
Website: ocuphire.com
Menu
OCUP OCUP Quote OCUP Short OCUP News OCUP Articles OCUP Message Board
Get OCUP Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUP - Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference

FARMINGTON HILLS, Mich., June 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonz...
OCUP - Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023

FARMINGTON HILLS, Mich., June 12, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation...

OCUP - Ocuphire Pharma GAAP EPS of -$0.28 misses by $0.13, revenue of $1.75M misses by $1.19M

2023-05-15 09:24:03 ET Ocuphire Pharma press release ( NASDAQ: OCUP ): Q1 GAAP EPS of -$0.28 misses by $0.13 . Revenue of $1.75M misses by $1.19M . For further details see: Ocuphire Pharma GAAP EPS of -$0.28 misses by $0.13, revenue of $1.75M misses by $1...

OCUP - Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis (RM) Set for September 28, 2023; Nyxol Development and Commerc...
OCUP - Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator

FARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations featur...

OCUP - Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs

PDUFA Date of September 28, 2023 Set for Nyxol ® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval Oral APX3330 End of Phase 2 Meeting with FDA Anticipated in 2023 to Align on Regulatory Path for Diab...

OCUP - FENG, ALXO and GFAI among mid-day gainers

2023-04-21 13:53:45 ET Gainers: Presto Automation ( PRST ) +49% . CBL International Limited ( BANL ) +34% . EyePoint Pharmaceuticals EYPT +31% . Asset Entities ( ASST ) +25% . ContextLogic ( WISH ) +24% . Mullen Automotive ( MU...
OCUP - EyePoint, Tenaya top healthcare gainers; Aditxt, Ocuphire among losers

2023-04-21 10:03:36 ET Gainers: EyePoint Pharmaceuticals ( EYPT ) +19% . Tenaya Therapeutics ( TNYA ) +21% . Community Health Systems ( CYH ) +11% . NovaBay Pharmaceuticals ( NBY ) +11% . Aziyo Biologics ( AZYO ) +8% . Loser...

OCUP - Ocuphire Pharma appoints Rick Rodgers as interim CEO

2023-04-21 08:50:22 ET Ocuphire Pharma ( NASDAQ: OCUP ) has appointed Rick Rodgers as Interim Chief Executive Officer and President, succeeding Mina Sooch. Ocuphire has retained an executive search firm to assist in identifying a permanent CEO. He has se...

OCUP - Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

FARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appoin...
Previous 10 Next 10